Bharat Immunologicals & Biologicals share price
BSE: 524663Pharmaceuticals & BiotechnologySmall Cap
Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1994
Last close ₹8.88down ₹0.40 (4.31%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹9.28.
28 Oct: open ₹9.40, high ₹9.40, low ₹8.70
52-week range of traded prices to 28 Oct 2026
₹7.11Low, 6 Oct 2026₹22.61High, 23 Dec 2025
- Under BSE's graded surveillance, stage 0, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹38 Cr3,103rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 17,962
Results
Standalone; ₹ crore.Bharat Immunologicals & Biologicals quarterly results
Quarter to Dec 2022, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.00 Crdown 100.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹4.68 CrQuarter to Sep 2022: −₹3.08 Cr
Revenue by quarter
Peak revenue ₹26 Cr, quarter to Sep 2022; lowest ₹0.00 Cr, quarter to Dec 2022
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 5 of the 6 quarters with results on record
| ₹ crore | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.2 | 24.7 | 17.4 | – | 10.5 | 26.5 | 0.0 |
| Net profit | 1.9 | −9.4 | −0.7 | – | −5.0 | −3.1 | −4.7 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | 13.6% | −37.9% | −3.8% | – | −47.7% | −11.6% | – |
Standalone. The last eight quarters. The latest is shaded. No results on record for the quarters to Mar 2021 and Mar 2022.
Year to Mar 2019, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹84 Crup 140.37%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹5.55 CrYear to Mar 2018: −₹4.26 Cr
- Net margin
- −6.6%
Revenue by year
Peak revenue ₹124 Cr, year to Mar 2017; lowest ₹2.84 Cr, year to Mar 2010
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 5 years with results on record
| ₹ crore | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | – | – | – | – | – | 124 | 35 | 84 |
| Net profit | −3 | −4 | – | – | – | – | – | 7 | −4 | −6 |
| Net margin | −113.0% | −149.1% | – | – | – | – | – | 5.4% | −12.2% | −6.6% |
Standalone. Years to March. The latest is shaded. No results on record for the years to Mar 2012, Mar 2013, Mar 2014, Mar 2015 and Mar 2016.
Business segments
Share of revenue, year to Mar 2019, standalone.Segment revenue and profit
- ORAL POLIO VACCINEORAL POLIO VACCINE, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹83.6 Cr99.9%
- ZINC DISPERSIBLE TABLETSZINC DISPERSIBLE TABLETS, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹0.1 Cr0.1%
- BIB SWEETS TABLETSBIB SWEETS TABLETS, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹0.0 Cr0.0%
Where the return came from
Yearly rates to Mar 2019, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −61.0% | – | – | 0.0% |
| 3 years | −25.3% | – | – | 0.0% |
| 5 years | −2.4% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Bharat Immunologicals & Biologicals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Bharat Immunologicals & Biologicals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Bharat Immunologicals & Biologicals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Mangalam Drugs and OrganicsMANGALAM | 46 | – | 0.45 | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 44 | – | 0.83 | −15.6% | – | −22.8% | −6.3% | 0.00% |
 Vasundhara RasayansVRL | 44 | 7.37 | 1.07 | +3.5% | +49.9% | 15.4% | 13.3% | 1.46% |
 Kabra DrugsKABRADG | 39 | 5.08 | 1.30 | +1,743.5% | – | 28.0% | 28.4% | 0.00% |
 Vista PharmaceuticalsVISTAPH | 38 | – | 1.04 | −60.4% | – | −28.7% | −32.5% | 0.00% |
 Medicamen OrganicsMEDIORG | 38 | – | – | −40.7% | −199.3% | −13.7% | – | 0.00% |
 Chandra Bhagat PharmaCBPL | 36 | 12.60 | 1.07 | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 36 | 20.09 | 0.81 | +4.2% | +10.3% | 4.1% | 5.3% | 2.72% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Bharat Immunologicals & Biologicals announcements
Sep 2026
30 Sep · Legal
Exchange has sought clarification from Bharat Immunologicals & Biologicals Corporation Ltd on September 30, 2026 with reference to significant movement in price, in order to ensure ....17 Sep · Announcement under Regulation 30 (LODR)-Winding-up
Aug 2024
7 Aug · Board meeting
Meeting on 16 Aug 2024
Feb 2024
29 Feb · Board meeting
Meeting on 8 Mar 2024
Bharat Immunologicals & Biologicals share price by year
Each calendar year to 2025.Bharat Immunologicals & Biologicals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 20.07 | −15.5% | 32.33 | 18.27 |
| 2024 | 23.74 | −32.8% | 40.44 | 23.06 |
| 2023 | 35.35 | −11.4% | 40.70 | 21.19 |
| 2022 | 39.90 | −31.7% | 56.60 | 22.70 |
| 2021 | 58.45 | +15.1% | 90.00 | 38.15 |
| 2020 | 50.80 | +588.3% | 50.80 | 5.69 |
| 2019 | 7.38 | −37.8% | 12.18 | 5.65 |
| 2018 | 11.86 | −65.6% | 36.95 | 11.63 |
| 2017 | 34.45 | +67.6% | 36.75 | 19.90 |
| 2016 | 20.55 | −33.0% | 32.15 | 16.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 27 Oct 2026 | 9.38 | 9.38 | 9.10 | 9.28 | 9.24 | 7,361 |
| 26 Oct 2026 | 9.37 | 9.37 | 8.63 | 9.09 | 9.03 | 14,086 |
| 23 Oct 2026 | 9.49 | 9.49 | 8.90 | 9.27 | 9.24 | 28,767 |
| 22 Oct 2026 | 9.05 | 9.45 | 8.75 | 9.18 | 9.03 | 21,709 |
| 21 Oct 2026 | 9.90 | 9.90 | 8.81 | 9.05 | 9.15 | 21,586 |
| 19 Oct 2026 | 9.71 | 9.90 | 9.52 | 9.55 | 9.64 | 17,122 |
| 16 Oct 2026 | 9.89 | 10.17 | 9.40 | 9.91 | 9.72 | 46,920 |
| 15 Oct 2026 | 9.50 | 10.10 | 9.50 | 9.88 | 9.86 | 50,231 |
| 14 Oct 2026 | 9.69 | 9.79 | 9.27 | 9.56 | 9.65 | 16,792 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 524663
- ISIN
- INE994B01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.bibcol.com
- CIN
- L24232UP1989GOI010542
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1989
- Registered office
- Village Chola, Bulandshahr 203203, Uttar Pradesh
- Share registrar
- MAS Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments